Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Repository of proposed pathways and protein-protein interaction networks in age-related macular degeneration

  • Pool, Fran M.
  • Kiel, Christina
  • Serrano Pubull, Luis, 1982-
  • Luthert, Philip J.
Age-related macular degeneration (AMD) is one of the commonest causes of sight loss in the elderly population and to date there is no intervention that slows or prevents early AMD disease progressing to blinding neovascularization or geographic atrophy. AMD is a complex disease and factors proposed to contribute to the development and progression of disease include aging, genetics, epigenetics, oxidative stress, pro-inflammatory state, and life-style factors such as smoking, alcohol, and high fat diet. Here, we generate a knowledge repository of pathways and protein-protein interaction (PPI) networks likely to be implicated in AMD pathogenesis, such as complement activation, lipid trafficking and metabolism, vitamin A cycle, oxidative stress, proteostasis, bioenergetics, autophagy/mitophagy, extracellular matrix (ECM) turnover, and choroidal vascular dropout. Two disctinct clusters ermerged from the networks for parainflamation and ECM homeostasis, which may represent two different disease modules underlying AMD pathology. Our analyses also suggest that the disease manifests primarily in RPE/choroid and less in neural retina. The use of standardized syntax when generating maps of these biological processes (SBGN standard) and networks (PSI standard) enables visualization of complex information in graphical programs such as CellDesigner and Cytoscape and enhances reusability and extension of data. The ability to focus onto subnetworks, multiple visualizations and simulation options will enable the AMD research community to computationally model subnetworks or to test experimentally new hypotheses arising from connectivities in the AMD pathway map., This work has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 634479 (EYE-RISK—to P.J.L., L.S., and C.K.). This work was supported by the Spanish Ministry of Economy and Competitiveness, Plan Nacional BIO2012-39754 and the European Fund for Regional Development (to L.S.). L.S. acknowledges the support of the Spanish Ministry of Economy and Competitiveness, “Centro de Excelencia Severo Ochoa 2013–2017” (SEV-2012-0208)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Simple and complex retinal dystrophies are associated with profoundly different disease networks

  • Kiel, Christina
  • Lastrucci, Claire
  • Luthert, Philip J.
  • Serrano Pubull, Luis, 1982-
Retinopathies are a group of monogenetic or complex retinal diseases associated with high unmet medical need. Monogenic disorders are caused by rare genetic variation and usually arise early in life. Other diseases, such as age-related macular degeneration (AMD), develop late in life and are considered to be of complex origin as they develop from a combination of genetic, ageing, environmental and lifestyle risk factors. Here, we contrast the underlying disease networks and pathological mechanisms of monogenic as opposed to complex retinopathies, using AMD as an example of the latter. We show that, surprisingly, genes associated with the different forms of retinopathies in general do not overlap despite their overlapping retinal phenotypes. Further, AMD risk genes participate in multiple networks with interaction partners that link to different ubiquitous pathways affecting general tissue integrity and homeostasis. Thus AMD most likely represents an endophenotype with differing underlying pathogenesis in different subjects. Localising these pathomechanisms and processes within and across different retinal anatomical compartments provides a novel representation of AMD that may be extended to complex disease in general. This approach may generate improved treatment options that target multiple processes with the aim of restoring tissue homeostasis and maintaining vision., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 634479 (EYE-RISK). This work was supported by the Spanish Ministerio de Economía y Competitividad, Plan Nacional BIO2012-39754 and the European Fund for Regional Development. We acknowledge the support of the Spanish Ministry of Economy and Competitiveness, 'Centro de Excelencia Severo Ochoa 2013-2017′. We acknowledge the support of the CERCA Programme/Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mediterranean Diet and Incidence of Advanced Age-Related Macular Degeneration: The EYE-RISK Consortium

  • Merle, Bénédicte M. J.
  • Colijn, Johanna M.
  • Cougnard-Grégoire, Audrey
  • Koning-Backus, Alexandra de
  • Delyfer, Marie Nöelle
  • Kiefte-de Jong, Jessica
  • Meester-Smoor, Magda
  • Féart, Catherine
  • Verzijden, Timo
  • Samieri, Cécilia
  • Franco, Oscar H.
  • Korobelnik, Jean-François
  • Klaver, Caroline C. W.
  • Delcourt, Cécilia
  • EYE-RISK Consortium
Purpose: To investigate associations of adherence to the Mediterranean diet (MeDi) with incidence of advanced age-related macular degeneration (AMD; the symptomatic form of AMD) in 2 European population-based prospective cohorts. Design: Prospective cohort study of the Rotterdam Study I (RS-I) and the Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires (Alienor) Study populations. Participants: Four thousand four hundred forty-six participants 55 years of age or older from the RS-I (The Netherlands) and 550 French adults 73 years of age or older from the Alienor Study with complete ophthalmologic and dietary data were included in the present study. Methods: Examinations were performed approximately every 5 years over a 21-year period (1990–2011) in RS-I and every 2 years over a 4-year period (2006–2012) in the Alienor Study. Adherence to the MeDi was evaluated using a 9-component score based on intake of vegetables, fruits, legumes, cereals, fish, meat, dairy products, alcohol, and the monounsaturated-to-saturated fatty acids ratio. Associations of incidence of AMD with MeDi were estimated using multivariate Cox proportional hazard models. Main Outcomes Measures: Incidence of advanced AMD based on retinal fundus photographs. Results: Among the 4996 included participants, 155 demonstrated advanced incident AMD (117 from the RS-I and 38 from the Alienor Study). The mean follow-up time was 9.9 years (range, 0.6–21.7 years) in the RS-I and 4.1 years (range, 2.5–5.0 years) in the Alienor Study. Pooling data for both the RS-I and Alienor Study, participants with a high (range, 6–9) MeDi score showed a significantly reduced risk for incident advanced AMD compared with participants with a low (range, 0–3) MeDi score in the fully adjusted Cox model (hazard ratio, 0.59; 95% confidence interval, 0.37–0.95; P = 0.04 for trend). Conclusions: Pooling data from the RS-I and Alienor Study, higher adherence to the MeDi was associated with a 41% reduced risk of incident advanced AMD. These findings support the role of a diet rich in healthful nutrient-rich foods such as fruits, vegetables, legumes, and fish in the prevention of AMD., The author(s) have made the following disclosure(s): B.M.J.M.: Consultant e Bausch & Lomb (Rochester, New York); Financial support e Laboratoires Théa (Clermont-Ferrand, France). A.C.-G.: Financial support e Laboratoires Théa (Clermont-Ferrand, France). M.-N.D.: Consultant e Bayer (Leverkusen, Germany), Allergan (Irvine, California), Novartis (Basel, Switzerland); Board membership e Bayer (Leverkusen, Germany), Allergan (Irvine, California), Novartis (Basel, Switzerland). O.H.F.: Financial support e Nestle (Vevey, Switzerland). J.-F.K.: Consultant e Alcon (Hünenberg, Switzerland), Alimera (Alpharetta, Georgia), Novartis (Basel, Switzerland), Roche (Basel, Switzerland), Thea (Clermont-Ferrand, France), Zeiss (Oberkochen, Germany), Bayer (Leverkusen, Germany). C.C.W.K.: Consultant e Bayer (Leverkusen, Germany); Lecturer e Novartis (Basel, Switzerland), Thea Pharma (Clermont-Ferrand, France). C.D.: Consultant e Allergan (Irvine, California), Bausch & Lomb (Rochester, New York), Laboratoires Théa (Clermont-Ferrand, France), Novartis (Basel, Switzerland), Roche (Basel, Switzerland); Financial support e Laboratoires Théa (Clermont-Ferrand, France), Essilor (Charenton le Pont, France). M.B.: Travel fees e Bayer (Leverkusen, Germany); Consultant e Roche (Basel, Switzerland). R.I., H.L., C.M., and E.N.: Employees e F. Hoffmann-La Roche Ltd (Basel, Switzerland). J.M.: Financial support e Bayer (Leverkusen, Germany), Alcon (Hünenberg, Switzerland), Ophthotech (New-York, NY), Notal Vision (Manassas, VA), Novartis (Basel, Switzerland), Roche (Basel, Switzerland). I.L.: Unrestricted research support e OPTOS Plc (Dunfermline, UK). Competing financial interest of members of the EYE-RISK consortium not otherwise disclosed: Verena Arndt, Sebastian Bühren, Tanja Endermann, and Markus Zumbansen are employees of AYOXXA. The EYE-RISK project is supported by the European Union’s Horizon 2020 Research and Innovation Programme (grant no.: 634479). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, The Netherlands; the Organization for the Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (DG XII), and the Municipality of Rotterdam, Rotterdam, The Netherlands. Additionally, the ophthalmic research within the Rotterdam Study was supported by the following foundations: Oogfonds; Bartiméus Sonneheerdt Vereniging; Landelijke Stichting voor Blinden en Slechtzienden; Algemene Nederlandse Vereniging Ter Voorkoming Van Blindheid; Novartis Foundation; and MaculaFonds, which contributed through UitZicht (grant nos.: 2015-36 and 2016-19). The funding organizations had no role in the design or conduct of this research and provided unrestricted grants. The Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires Study is funded by Laboratoires Théa; Fondation Voir et Entendre; Retina France; Agence Nationale de la Recherche (ANR 2010-PRSP-011 VISA); and Caisse Nationale pour la Solidarité et l’Autonomie.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Retinal pigment epithelium degeneration caused by aggregation of PRPF31 and the role of HSP70 family of proteins

  • Valdés-Sánchez, María Lourdes
  • Calado, Sofia M.
  • Cerda, Berta de la
  • Aramburu del Boz, Ana
  • García-Delgado, Ana B.
  • Massalini, Simone
  • Montero-Sánchez, Adoración
  • Bhatia, Vaibhav
  • Rodríguez-Bocanegra, Eduardo
  • Díez-Lloret, Andrea
  • Rodriguez-Martinez, Daniel
  • Chakarova, Christina
  • Bhattacharya, Shom Shanker
  • Díaz-Corrales, Francisco J.
Background Mutations in pre-mRNA splicing factor PRPF31 can lead to retinitis pigmentosa (RP). Although the exact disease mechanism remains unknown, it has been hypothesized that haploinsufficiency might be involved in the pathophysiology of the disease. Methods In this study, we have analyzed a mouse model containing the p.A216P mutation in Prpf31 gene. Results We found that mutant Prpf31 protein produces cytoplasmic aggregates in the retinal pigment epithelium and decreasing the protein levels of this splicing factor in the nucleus. Additionally, normal protein was recruited in insoluble aggregates when the mutant protein was overexpressed in vitro. In response to protein aggregation, Hspa4l is overexpressed. This member of the HSP70 family of chaperones might contribute to the correct folding and solubilization of the mutant protein, allowing its translocation to the nucleus. Conclusions Our data suggests that a mechanism haploinsufficiency and dominant-negative is involved in retinal degeneration due to mutations in PRPF31. HSP70 over-expression might be a new therapeutic target for the treatment of retinal degeneration due to PRPF31 mutations., This project has been financed through a) The ISCIII (Miguel Servet-I, 2015), co-financed by the European Regional Development Fund (ERDF), No CP15/00071. b) The European Union’s Horizon 2020 research and innovation program, under grant agreement No 634479. c) Regional Ministry of Economy, Innovation and Science of the Junta de Andalucía, No P09-CTS-04967.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Repository of proposed pathways and protein-protein interaction networks in age-related macular degeneration

  • Pool, Fran M.
  • Kiel, Christina
  • Serrano Pubull, Luis, 1982-
  • Luthert, Philip J.
Age-related macular degeneration (AMD) is one of the commonest causes of sight loss in the elderly population and to date there is no intervention that slows or prevents early AMD disease progressing to blinding neovascularization or geographic atrophy. AMD is a complex disease and factors proposed to contribute to the development and progression of disease include aging, genetics, epigenetics, oxidative stress, pro-inflammatory state, and life-style factors such as smoking, alcohol, and high fat diet. Here, we generate a knowledge repository of pathways and protein-protein interaction (PPI) networks likely to be implicated in AMD pathogenesis, such as complement activation, lipid trafficking and metabolism, vitamin A cycle, oxidative stress, proteostasis, bioenergetics, autophagy/mitophagy, extracellular matrix (ECM) turnover, and choroidal vascular dropout. Two disctinct clusters ermerged from the networks for parainflamation and ECM homeostasis, which may represent two different disease modules underlying AMD pathology. Our analyses also suggest that the disease manifests primarily in RPE/choroid and less in neural retina. The use of standardized syntax when generating maps of these biological processes (SBGN standard) and networks (PSI standard) enables visualization of complex information in graphical programs such as CellDesigner and Cytoscape and enhances reusability and extension of data. The ability to focus onto subnetworks, multiple visualizations and simulation options will enable the AMD research community to computationally model subnetworks or to test experimentally new hypotheses arising from connectivities in the AMD pathway map., This work has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 634479 (EYE-RISK—to P.J.L., L.S., and C.K.). This work was supported by the Spanish Ministry of Economy and Competitiveness, Plan Nacional BIO2012-39754 and the European Fund for Regional Development (to L.S.). L.S. acknowledges the support of the Spanish Ministry of Economy and Competitiveness, “Centro de Excelencia Severo Ochoa 2013–2017” (SEV-2012-0208)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Simple and complex retinal dystrophies are associated with profoundly different disease networks

  • Kiel, Christina
  • Lastrucci, Claire
  • Luthert, Philip J.
  • Serrano Pubull, Luis, 1982-
Retinopathies are a group of monogenetic or complex retinal diseases associated with high unmet medical need. Monogenic disorders are caused by rare genetic variation and usually arise early in life. Other diseases, such as age-related macular degeneration (AMD), develop late in life and are considered to be of complex origin as they develop from a combination of genetic, ageing, environmental and lifestyle risk factors. Here, we contrast the underlying disease networks and pathological mechanisms of monogenic as opposed to complex retinopathies, using AMD as an example of the latter. We show that, surprisingly, genes associated with the different forms of retinopathies in general do not overlap despite their overlapping retinal phenotypes. Further, AMD risk genes participate in multiple networks with interaction partners that link to different ubiquitous pathways affecting general tissue integrity and homeostasis. Thus AMD most likely represents an endophenotype with differing underlying pathogenesis in different subjects. Localising these pathomechanisms and processes within and across different retinal anatomical compartments provides a novel representation of AMD that may be extended to complex disease in general. This approach may generate improved treatment options that target multiple processes with the aim of restoring tissue homeostasis and maintaining vision., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 634479 (EYE-RISK). This work was supported by the Spanish Ministerio de Economía y Competitividad, Plan Nacional BIO2012-39754 and the European Fund for Regional Development. We acknowledge the support of the Spanish Ministry of Economy and Competitiveness, 'Centro de Excelencia Severo Ochoa 2013-2017′. We acknowledge the support of the CERCA Programme/Generalitat de Catalunya.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Multiplex bioimaging of proteins-related to neurodegenerative diseases in eye sections by laser ablation - inductively coupled plasma – mass spectrometry using metal nanoclusters as labels

  • Lores Padín, Ana|||0000-0002-5564-591X
  • Fernández García, Beatriz|||0000-0002-2592-1442
  • Álvarez, Lydia
  • González Iglesias, Héctor|||0000-0001-5251-0967
  • Lengyel, I.
  • Pereiro García, María Rosario|||0000-0002-5936-7726
This work was financially supported through project CTQ2016- 79015-R by Agencia Estatal de Investigación (Spain) and FEDER. A. Lores-Padín and B. Fernández respectively acknowledge the FPU Grant (Ref. MECD-17-FPU16/01363; Ministry of Education) and the contract RYC-2014-14985 through the “Ramón y Cajal Program” (Ministry of Economy and Competitiveness). This research was also supported by a grant from the Belfast Association for the Blind and the “Eye-Risk” European Union’s Horizon 2020 research and innovation program (grant ref.: 634479) (I.L).